Advertisement
In Brief

AACI publishes report on staff retention at clinical trials offices

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The AACI CTO Staff Retention Task Force published a report that highlights key data from two surveys distributed to cancer center directors in March 2022 and again in March 2023. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.
Clinical Roundup

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels. 
Advertisement
Advertisement